Owner Scorecard


← All companies ← TLK Manual TM → ← TLRY Pharmaceuticals TNGX →

TLX, Telix Pharmaceuticals Limited

Pharmaceuticals consumer brand Distress / turnaround

A pharmaceutical business, where patents grant a temporary monopoly the pipeline must keep refilling.

Latest annual: FY2025 20-F · 1 ADS = 1 ordinary share
TLX · Telix Pharmaceuticals Limited
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$804M
+55.6% YoY
Vital signs · TTM, with 3-yr average
Revenue $804M 3-yr avg $551M
Gross margin 53% 3-yr avg 60%
Operating margin 3.7% 3-yr avg 5.9%
ROIC 3% 3-yr avg 22%
Owner-earnings margin −5% 3-yr avg 1%
Free cash flow margin −5% 3-yr avg 0%

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
What moves the needle
Gross margin has run about 63% and operating margin about 3.7% through the cycle, a wide spread between price and the cost of what it sells — whether that advantage is durable pricing power or a margin that can erode is the question the record is for. The operating margin has swung widely — from 3.3% to 11% — on a steadier 63% gross margin, so what moves it sits below the gross line, in operating spend and one-off charges more than in the cost of the product itself. The cash cycle has run negative through the cycle (a median of −66 days): the operation is paid before it pays, so working capital releases cash as the business grows rather than tying it up. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has run in the teens (median 18%, above 15% in 2 of 3 years). Owner earnings, the cash-based check, have been thin too. Returns like these are solid but short of clear franchise economics; whether they hold is what the 10-K settles, not the multiple.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2023–2025

realized figures from each filing · older years to the left
2023’232024’242025’25TTMTTMDec 2025
Income statement
$333M$517M$804M$804MRevenueRevenue
63%65%53%53%Gross marginGross mgn
$11M$55M$30M$30MOperating incomeOp. inc.
3.3%10.7%3.7%3.7%Operating marginOp. mgn
$4M$34M($7M)($7M)Net incomeNet inc.
Cash flow & returns
$14M$27M($17M)($17M)Operating cash flowOp. cash
$4M$5M$22M$22MDepreciationDeprec.
$6M($11M)($32M)($32M)Working capital & otherWC & other
$6M$9M$26M$26MCapexCapex
1.9%1.8%3.2%3.2%Capex / revenueCapex/rev
$10M$23M($43M)($43M)Owner earningsOwner earn.
2.9%4.4%−5.3%−5.3%Owner earnings marginOE mgn
$8M$18M($43M)($43M)Free cash flowFCF
2.4%3.6%−5.3%−5.3%Free cash flow marginFCF mgn
44%18%3%3%ROICROIC
4%10%-2%-2%Return on equityROE
4%10%−2%−2%Retained to equityRetained/eq
Balance sheet
$84M$440M$142M$142MCash & investmentsCash+inv
$44M$87M$129M$129MReceivablesReceiv.
$13M$24M$37M$37MInventoryInvent.
$54M$87M$150M$150MAccounts payablePayables
$2M$24M$16M$16MOperating working capitalOper. WC
$159M$570M$330M$330MCurrent assetsCur. assets
$111M$205M$232M$232MCurrent liabilitiesCur. liab.
1.4×2.8×1.4×1.4×Current ratioCurr. ratio
$67M$199M$199MGoodwillGoodwill
$277M$940M$1.2B$1.2BTotal assetsAssets
$7M$354M$405M$405MTotal debtDebt
($78M)($86M)$263M$263MNet debt / (cash)Net debt
1.2×2.3×0.7×0.7×Interest coverageInt. cov.
$103M$353M$415M$415MShareholders’ equityEquity
Per share
319M331M338M338MShares out (diluted)Shares
$1.04$1.56$2.38$2.38Revenue / shareRev/sh
$0.01$0.10$-0.02$-0.02EPS (diluted)EPS
$0.03$0.07$-0.13$-0.13Owner earnings / shareOE/sh
$0.02$0.06$-0.13$-0.13Free cash flow / shareFCF/sh
$0.02$0.03$0.08$0.08Cap. spending / shareCapex/sh
$0.32$1.07$1.23$1.23Book value / shareBVPS

The record, charted

FY2023–2025

Each measure over its full record; the current point and the worst year marked.

Share count
338Mpeak FY2025
ROIC
3%low FY2025
Gross margin
53%low FY2025

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

($43M)owner earningsvs.($7M)net incomelow FY2025

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business reported a $7M loss but ($43M) of owner earnings: $36M less than the profit line, taken out by capital spending and the timing of cash.

FY2025FY2024FY2023
Reported net income($7M)$34M$4M
Depreciation & amortizationnon-cash charge added back+$22M+$5M+$4M
Working capital & othertiming of cash in and out, other non-cash items−$32M−$11M+$6M
Cash from operations($17M)$27M$14M
Maintenance capital expenditurethe spending needed just to hold position and volume−$26M−$5M−$4M
Owner earnings($43M)$23M$10M
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−$4M−$2M
Free cash flow($43M)$18M$8M
Owner-earnings marginowner earnings ÷ revenue-5%4%3%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 20-F · source on SEC EDGAR →
Material weakness in financial controls
“We have identified a material weakness in our internal control over financial reporting.”

The figures below are only as sound as the controls that produced them. read the note →

Will it survive?

  • Does not cover its interest
    Operating income $30M ÷ interest expense $41M
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • How heavy is the debt, net of cash? $263M · 8.8× operating profit
    Heavy net debt
    Cash $142M − debt $405M
    What this means

    Netting $142M of cash and short-term investments against $405M of debt leaves $263M owed, about 8.8× a year's operating profit (13.6× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Negative, funded by others
    DSO 59 + DIO 36 − DPO 145 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. A negative cycle is a quiet moat: suppliers and customers fund the operation (Buffett's “float”), the company grows on other people's money.

Is it a good business?

  • High through the cycle
    3-yr median, range 3%–44%; 3% latest = NOPAT $24M ÷ invested capital $679M
    Industry peers: median 6%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 3 years (it ran 3% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • Thin through the cycle
    3-yr median margin, range -5%–4%; latest ($43M) = operating cash ($17M) − maintenance capex $26M
    Industry peers: median 17%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -5% of revenue this year, a 3% median across 3 years.

  • Loss, and burning cash
    Net income ($7M) · cash from operations ($17M)

    In the filing’s words The filing discloses a material weakness in its financial controls — the reported numbers here, and the record built on them, are only as reliable as the controls that produced them.

    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 1.19×
    Maintaining
    Capex $26M ÷ depreciation $22M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 0 of 3 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $804M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Miss
    Current ratio ≥ 2× · 1.43×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Miss
    Debt ≤ working capital · $405M vs $99M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $0.03/share (latest year $-0.02), the averaged base the calculator's gate runs on, and book value is $1.23/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

In its own filing A competitive risk, new this year

Its FY2025 10-K names artificial intelligence as a competitive threat, in language that was not in the prior year's filing.

“Our failure to use AI technologies in a way that maintains trust, quality and control in our business activities and to capitalize on opportunities presented by AI may also place us at a competitive disadvantage.”

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of fiscal year-end, Dec 31, 2025

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$330M
  • Cash & short-term investments$142M
  • Receivables$129M
  • Inventory$37M
  • Other current assets$22M
Current liabilities$232M
  • Debt due within a year$13M
  • Accounts payable$150M
  • Other current liabilities$68M
Current ratio1.43×all current assets ÷ what's due · Graham looked for 2×
Quick ratio1.27×stricter: inventory excluded
Cash ratio0.61×strictest: cash alone against what's due
Working capital$99Mthe cushion left after near-term bills
Debt due this year vs. cash$13M due · $142M cash covered by cash on hand, no refinancing forced · both figures from the Dec 31, 2025 balance sheet
Cash runway3.3 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Deeper floors
Tangible book value($376M)equity stripped of goodwill & intangibles
Net current asset value($418M)Graham's net-net: current assets less all liabilities
Debt incl. operating leases$467M$62M of it operating leases
Deferred revenue$402Kcustomer cash collected before delivery; operating float

From the company's latest filing.

Acquisitions & goodwill

from the balance sheet & the 3-year cash-flow record

Goodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.

Goodwill & intangibles$792M68% of all assets; the premium carried on the balance sheet for businesses acquired
Against book equity48%goodwill is this share of book equity; the rest is the company’s own retained and paid-in capital
Cash spent acquiring$0over 3 years buying other businesses, against $41M of capital spent building

None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.

Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and write-downs summed across the 3-year record, from the company's own filings.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
ANIPANI Pharmaceuticals Inc.$883M62%8.8%4%17%
HRMYHarmony Biosciences Holdings Inc.$868M79%26.7%38%32%
ARWRArrowhead Pharmaceuticals$829M-106.8%-51%-77%
TLXTelix Pharmaceuticals Limited$804M63%3.7%18%3%
COLLCollegium Pharmaceutical Inc.$781M56%6.8%44%31%
CORTCorcept Therapeutics Incorporated$761M98%30.6%25%34%
EBSEmergent BioSolutions Inc.$743M58%12.5%6%8%
PCRXPacira BioSciences$726M73%3.7%2%16%
Group median63%7.8%12%16%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Enter the US price, in dollars: the NYSE/Nasdaq quote you hold. Per the filing's own cover, “American depositary shares , each representing one ordinary”; Telix Pharmaceuticals Limited reports in USD, so every figure in this tool is stated per ADS so your dollar quote reconciles exactly. The record tables elsewhere on this page remain as filed.

Telix Pharmaceuticals Limited is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today−5%

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Telix Pharmaceuticals Limited (TLX), the owner's record," https://ownerscorecard.com/c/TLX, data as of 2026-07-09.

Manual order: ← TLK its page in the Manual TM →

Industry order: ← TLRY the Pharmaceuticals chapter TNGX →